Murciano-Goroff, Yonina R.
Schram, Alison M. http://orcid.org/0000-0002-6070-2413
Rosen, Ezra Y.
Won, Helen
Gong, Yixiao
Noronha, Anne Marie
Janjigian, Yelena Y.
Stadler, Zsofia K.
Chang, Jason C.
Yang, Soo-Ryum
Mandelker, Diana http://orcid.org/0000-0003-4154-0567
Offit, Kenneth
Berger, Michael F. http://orcid.org/0000-0003-3882-5000
Donoghue, Mark T. A.
Bandlamudi, Chaitanya http://orcid.org/0000-0003-1108-4919
Drilon, Alexander http://orcid.org/0000-0001-6806-9061
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
Article History
Received: 27 September 2021
Accepted: 12 October 2022
First Online: 23 November 2022
Competing interests
: Y.R.M.-G. acknowledges receipt of travel, accommodation, and expenses from AstraZeneca as well as honoraria from Virology Education and Projects in Knowledge (CME program funded by an educational grant from Amgen). She further acknowledges research funding paid to the institution from Loxo Oncology at Eli Lilly, Elucida Oncology, Taiho Oncology, Hengrui Pharmaceutical/Jiangsu Hengrui Pharmaceuticals, Luzsana Biotechnology, and Endeavor Biomedicines. She acknowledges royalties from Rutgers University Press and Wolters Kluwer. A.M.S. has received advisory board compensation from Relay Therapeutics and research funding paid to the institution from AstraZeneca, ArQule, BeiGene, Black Diamond Therapeutics, Kura, Lilly, Merus, Northern Biologics, Pfizer, Relay, and Surface Oncology. Y.Y.J. acknowledges research funding from the National Cancer Institute, Department of Defense, Cycle for Survival, Fred’s Team, RGENIX, Bayer, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly, and Merck. She has served on advisory boards and/or done consulting for Bristol-Myers Squibb, Merck Serono, Merck, Eli Lilly, Daiichi-Sankyo, Pfizer, Bayer, Imugene, AstraZeneca, Zymeworks Inc., Seattle Genetics, Basilea Pharmaceutica, RGENIX, as well as Michael J. Hennessy Associates and Paradigm Medical Communications. She also holds stock options in RGENIX. Zsofia K. Stadler’s immediate family member serves as a consult in Ophthalmology for Alcon, Adverum, Gyroscope Therapeutics Limited, Neurogene, and RegenexBio, outside the submitted work. M.F.B. has received research funding from Grail and has a provisional patent pending for “Systems and Methods for Detecting Cancer via cfDNA screening” (WO2019204208A1). A.D. has received honoraria or worked on the advisory boards of Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Liberum, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica Ltd, mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc, AiCME, i3 Health, MonteRosa. He reports equity in Treeline Bio. He reports copyright in Selpercatinib-Osimertinib (filed/pending). He reports associated research paid to the institution from: Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar. He has received research support from Foundation Medicine. He notes royalties from: Wolters Kluwer. He has other support from Boehringer Ingelheim. He acknowledges other support (including food/beverages) from Merck, Puma, Merus, and Boehringer Ingelheim. He has received CME honoraria from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, EPG Health, JNCC/Harborside, Liberum, and Remedica Ltd. All remaining authors have no conflicts to declare.